Malgorzata Kolodziej

Prof. Dr. Malgorzata Kolodziej


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2015 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
KGK. Graf
K. Graf
TKT. Kohl
T. Kohl
BNB. A. Neubauer
B. A. Neubauer
FDF. Dey
F. Dey
DFD. Faas
D. Faas
MKMalgorzata Kolodziej
Malgorzata Kolodziej
Objective: To evaluate the need for postnatal neurosurgical intervention after fetoscopic patch coverage of spina bifida aperta (SBA).Methods: This was a retrospective analysis of a cohort of 71 fetuses which underwent minimally invasive fetoscopic patch coverage of SBA between 21 + 0 and 29 + 1 weeks of gestation. Postnatal neurosurgical procedures were classified into two types: re‐coverage of the SBA within the first 3 months following birth, and shunt placement as treatment of associated hydrocephalus within the first year.Results: Location of the SBA was lumbosacral in 59 cases, lumbar in seven, thoracic in three and sacral in two. In total, 20/71 (28%) patients underwent early postnatal neurosurgical intervention by means of re‐coverage of the SBA. This was performed because of cerebrospinal fluid leakage in seven (35%), adhesions with functional deterioration in three (15%), incomplete coverage in five (25%) and skin defect in five (25%) cases. Ventriculoperitoneal shunt placement within 1 year was required in 32 (45%) cases and was preceded by ventriculostomy in two. Three (4%) infants needed Chiari decompression surgery in the first 12 months following birth, because of syringomyelia or gait disturbance.Conclusions: Fetoscopic patch coverage of SBA may require postnatal re‐coverage in some cases. In most cases, conservative wound treatment shows good results, without requiring neurosurgical intervention. The low 1‐year‐shunt rate is comparable to data of the Management of Myelomeningocele Study and lower compared with published data of patients with postnatal only coverage of SBA. Copyright © 2015 ISUOG. Published by John Wiley & Sons Ltd.

6 June 2014 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
KQKarl Quint
Karl Quint
NSNorbert Stiel
Norbert Stiel
DNDaniel Neureiter
Daniel Neureiter
HSHans Ulrich Schlicker
Hans Ulrich Schlicker
Christopher NimskyChristopher Nimsky
Christopher Nimsky
MKMalgorzata Kolodziej
Malgorzata Kolodziej

9 September 2015 in Journal of Neurological Surgery Part A: Central European Neurosurgery
Verified
Journal Article
Closed access
PDF file
DHDieter Hellwig
Dieter Hellwig
Christopher NimskyChristopher Nimsky
Christopher Nimsky
LBLudwig Benes
Ludwig Benes
MKMalgorzata Kolodziej
Malgorzata Kolodziej
Objective Motor cortex stimulation (MCS) is an alternative treatment modality for central neuropathic pain, if conservative treatment failed. Study aim was outcome assessment after MCS. Material and Methods This study is a retrospective case series review of patients who had undergone MCS for central pain (n = 8), deafferentation pain (n = 3) and neuropathic trigeminal pain (n = 9) between April 2001 and May 2011. In all patients, four contact-paddle electrodes were placed in the epidural space overlying the motor cortex via burr hole trepanation under local anesthesia. The follow-up period was 6 months to 6 years. Pain control was assessed by the visual analog scale (VAS). Results A total of 22 patients (11 men, 11 women) were treated; after trial stimulation two male patients were excluded for incompliance reasons. The mean patient age was 59.8 years (range: 31–79 years). In the central pain group, three patients reported complete, and four patients satisfactory pain control. In the trigeminal neuropathic pain group, seven patients reported complete, and two patients satisfactory pain control. In the deafferentation pain group, one patient reported complete, and two patients satisfactory pain control. None of the patients showed new neurologic deficits after the MCS. Conclusions MCS is an effective treatment modality for central neuropathic pain and trigeminal pain with low morbidity and mortality. Future studies are necessary to evaluate and optimize this treatment option in more detail.

11 November 2015 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
PDF file
Marco SteinMarco Stein
Marco Stein
BMBjörn Misselwitz
Björn Misselwitz
GHGerhard F. Hamann
Gerhard F. Hamann
MKMalgorzata Kolodziej
Malgorzata Kolodziej
MRMarcus H.T. Reinges
Marcus H.T. Reinges
EUEberhard Uhl
Eberhard Uhl

1 March 2016
Verified
Journal Article
Closed access
MKMalgorzata Kolodziej
Malgorzata Kolodziej
CWCornelia Weischer
Cornelia Weischer
MRMarcus Reinges
Marcus Reinges
EUEberhard Uhl
Eberhard Uhl
MWMarcus A Weigand
Marcus A Weigand
Marco SteinMarco Stein
Marco Stein

25 August 2020 in International Journal of Oncology
Verified
Journal Article
Closed access
PDF file
MKMalgorzata Kolodziej
Malgorzata Kolodziej
BBB. Al Barim
B. Al Barim
JNJ. Nagl
J. Nagl
MWM. A. Weigand
M. A. Weigand
EUE. Uhl
E. Uhl
MSM. Stein
M. Stein
Sphingosine‑1‑phosphate (S1P) plays a key role in cell survival, growth, migration, and in angiogenesis. In glioma, it triggers the activity of the S1P‑receptor 1 and of the sphingosine kinase 1; thus influencing the survival rate of patients. The aim of the present study was to investigate the anti‑proliferative effect of the S1P analogue FTY720 (fingolimod) in glioblastoma (GBM) cells. A172, G28, and U87 cells were incubated with micromolar concentrations of FTY720 or temozolomide (TMZ) for 24 to 72 h. Proliferation and half maximal inhibitory concentration (IC50) were determined by using the xCELLigence system. FACS analysis was performed to check the cell cycle distribution of the cells after a 72‑h incubation with FTY720. This was then compared to TMZ‑incubated and to untreated cells. Gene expression was detected by RT‑qPCR in A172, G28, U87 and three primary GBM‑derived cell lines. FTY720 was able to reduce the number of viable cells. The IC50 value was 4.6 µM in A172 cells, 17.3 µM in G28 cells, and 25.2 µM in U87 cells. FTY720 caused a significant arrest of the cell cycle in all cells and stabilized or over‑expressed the level of AKT1, MAPK1, PKCE, RAC1, and ROCK1 transcripts. The TP53 transcript level remained stable or was downregulated after treatment with FTY720. FTY720 may be a promising target drug for the treatment of GBM, as it has a strong anti‑proliferative effect on GBM cells.